换一批
换一批Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospective case series clinical trial.
作者：
关键词
Hedgehog pathway inhibitoradvanced basal cell carcinomaadverse eventsalopeciabasal cell carcinomabasal cell carcinoma histopathologycancerdysgeusiahigh risk basal cell carcinomahistologic clearancehistologic featureshistopathologic subtype of basal cell carcinomahistopathologyinfiltrativelocally advanced basal cell carcinomamuscle spasmsnodularsafetyshort course therapyshort-term therapysuperficialtolerabilitytumor responsevismodegib
主题词
投药, 口服(Administration, Oral);成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);秃发(Alopecia);酰苯胺类(Anilides);抗肿瘤药(Antineoplastic Agents);活组织检查(Biopsy);癌, 基底细胞(Carcinoma, Basal Cell);用药计划表(Drug Administration Schedule);味觉异常(Dysgeusia);女(雌)性(Female);随访研究(Follow-Up Studies);人类(Humans);男(雄)性(Male);中年人(Middle Aged);肿瘤复发, 局部(Neoplasm Recurrence, Local);前瞻性研究(Prospective Studies);吡啶类(Pyridines);皮肤(Skin);皮肤肿瘤(Skin Neoplasms);痉挛(Spasm);治疗结果(Treatment Outcome)
DOI
10.1016/j.jaad.2019.12.002
PMID
31836564
发布时间
2020-11-10
- 浏览3
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
